atrasentan has been researched along with bosentan anhydrous in 24 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (bosentan anhydrous) | Trials (bosentan anhydrous) | Recent Studies (post-2010) (bosentan anhydrous) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 1,836 | 215 | 630 |
| Protein | Taxonomy | atrasentan (IC50) | bosentan anhydrous (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | 0.095 | |
| Endothelin receptor type B | Homo sapiens (human) | 0.3044 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.2317 | |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | 0.0047 | |
| Endothelin-1 receptor | Sus scrofa (pig) | 0.0075 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 15 (62.50) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Dixon, DB; Jae, HS; Marsh, KC; Nguyen, B; Opgenorth, TJ; von Geldern, TW; Winn, M | 1 |
| Berens, KL; Blok, N; Bourgoyne, AR; Brock, TA; Bui, H; Decker, ER; Dixon, RA; Holland, GW; Knowles, V; Wang, J; Wu, C; You, TJ | 1 |
| Aubert, JD; Juillerat-Jeanneret, L | 1 |
| Chiou, WJ; Hoffman, DJ; Opgenorth, TJ; von Geldern, TW; Winn, M; Wu-Wong, JR | 1 |
| Chiou, WJ; Dixon, DB; Opgenorth, TJ; Wu-Wong, JR | 1 |
| Best, PJ; Hasdai, D; Holmes, DR; Lerman, A; McKenna, CJ | 1 |
| Chen, YF; Oparil, S | 1 |
| Enseleit, F; Hürlimann, D; Lüscher, TF; Noll, G; Ruschitzka, F | 1 |
| Guimarães, CL; Rae, GA; Trentin, PG | 1 |
| Carducci, MA; Lassiter, LK | 1 |
| Fujimori, A; Miyata, K; Noguchi, Y; Ohtake, A; Sasamata, M; Sato, S; Sudoh, K; Ukai, M; Yuyama, H | 1 |
| Shi, GY | 1 |
| Bäcker, A; Cervenka, L; Kramer, HJ; Opocensky, M; Vanêcková, I; Vernerová, Z | 1 |
| Chichorro, JG; Rae, GA; Souza, GE; Zampronio, AR | 1 |
| Chichorro, JG; Rae, GA; Zampronio, AR | 1 |
| Bäcker, A; Cervenka, L; Dvorák, P; Eis, V; Kramer, HJ; Opocenský, M; Schejbalová, S; Vanecková, I; Vernerová, Z | 1 |
| Lalich, M; Liu, G; McNeel, DG; Wilding, G | 1 |
| Chang, NC; Chen, CC; Lee, TM; Lin, MS | 1 |
| Benderitter, M; Blirando, K; François, A; Jullien, N; Milliat, F; Sabourin, JC | 1 |
| Bäcker, A; Cervenka, L; Kramer, HJ; Kujal, P; Vaneckova, I; Vernerová, Z | 1 |
| Ariaans, MP; Brookes, ZL; Brown, NJ; Kaufman, S; Mansart, A; Reilly, CS; Ross, JJ; Ruff, LJ | 1 |
| Ergul, A; Li, W; Sachidanandam, K | 1 |
| Cheng, G; Li, B; Li, Y; Liu, D; Lu, S; Xiao, J; Yuan, W; Zhao, Z | 1 |
| Chi, J; Dong, B; Huang, Y; Lv, W; Wang, YG; Zhou, Y | 1 |
8 review(s) available for atrasentan and bosentan anhydrous
| Article | Year |
|---|---|
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrosis; Humans; Hypertension, Pulmonary; Neoplasms; Receptors, Endothelin | 2016 |
Endothelial dysfunction in the pulmonary vascular bed.
Topics: Animals; Antihypertensive Agents; Atrasentan; Bosentan; Controlled Clinical Trials as Topic; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Hypoxia; Lung Diseases, Obstructive; Nitric Oxide; Oligopeptides; Peptides, Cyclic; Piperidines; Pulmonary Circulation; Pyrrolidines; Receptors, Endothelin; RNA, Messenger; Sulfonamides; Time Factors; Vasoconstriction; Vasodilation | 2000 |
Endothelin antagonists and heart failure.
Topics: Atrasentan; Bosentan; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Hemodynamics; Humans; Hypertension; Pyrrolidines; Receptors, Endothelin; Sulfonamides | 2002 |
Endothelin receptor antagonists in the treatment of prostate cancer.
Topics: Androgen Antagonists; Apoptosis; Atrasentan; Bone Neoplasms; Bosentan; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Forecasting; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Sulfonamides; Treatment Outcome | 2003 |
Endothelin receptor antagonists in cancer therapy.
Topics: Atrasentan; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Signal Transduction; Sulfonamides | 2007 |
End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade.
Topics: Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Bosentan; Disease Models, Animal; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heterozygote; Homozygote; Hypertension; Male; Podocytes; Pyrrolidines; Rats; Rats, Transgenic; Receptor, Endothelin A; Receptor, Endothelin B; Renin; Sodium Chloride, Dietary; Sulfonamides; Time Factors | 2009 |
Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis.
Topics: Antihypertensive Agents; Atrasentan; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension; Middle Aged; Models, Statistical; Phenylpropionates; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Tetrazoles | 2017 |
Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
Topics: Albuminuria; Atrasentan; Bosentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Heart Failure; Humans; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic | 2021 |
1 trial(s) available for atrasentan and bosentan anhydrous
| Article | Year |
|---|---|
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Isoxazoles; Ligands; Male; Models, Molecular; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Structure-Activity Relationship; Sulfones | 2004 |
15 other study(ies) available for atrasentan and bosentan anhydrous
| Article | Year |
|---|---|
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
Topics: Administration, Oral; Animals; Atrasentan; Endothelin Receptor Antagonists; Half-Life; Male; Models, Chemical; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Structure-Activity Relationship | 1997 |
Endothelins and endothelin receptor antagonists: binding to plasma proteins.
Topics: 3T3 Cells; Acetamides; Animals; Atrasentan; Blood Proteins; Bosentan; CHO Cells; Cricetinae; Dioxoles; Endothelin Receptor Antagonists; Endothelins; Humans; Iodine Radioisotopes; Mice; Protein Binding; Pyrrolidines; Radioligand Assay; Rats; Serum Albumin; Sulfonamides; Swine | 1996 |
Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristics.
Topics: Acetamides; Animals; Atrasentan; Azepines; Binding, Competitive; Bosentan; Cells, Cultured; CHO Cells; Cricetinae; Dioxoles; Endothelin Receptor Antagonists; Endothelin-1; Hydrolysis; Indoles; Phosphatidylinositols; Pyrrolidines; Rats; Serum Albumin, Bovine; Sulfonamides; Swine | 1997 |
Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia.
Topics: Administration, Oral; Animals; Atrasentan; Bosentan; Coronary Vessels; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelium, Vascular; Hemodynamics; Hypercholesterolemia; Pyrrolidines; Random Allocation; Receptor, Endothelin A; Sulfonamides; Swine | 1999 |
Endothelin ET(B) receptor-mediated mechanisms involved in oleic acid-induced acute lung injury in mice.
Topics: Acute Disease; Analysis of Variance; Animals; Atrasentan; Bosentan; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Evans Blue; Lung; Male; Mice; Mice, Inbred Strains; Neutrophil Infiltration; Oleic Acid; Pyrimidines; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Respiratory Distress Syndrome; Sulfonamides | 2002 |
Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist.
Topics: Administration, Oral; Animals; Atrasentan; Binding, Competitive; Biological Availability; Blood Pressure; Bosentan; Cell Line, Tumor; Cells, Cultured; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Injections, Intravenous; Muscle, Smooth, Vascular; Oligopeptides; Peptides, Cyclic; Piperidines; Pyrimidines; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Viper Venoms | 2004 |
[New choice of therapy of pulmonary hypertension: endothelin receptor antagonist].
Topics: Adult; Atrasentan; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Pyrimidines; Pyrrolidines; Sulfonamides | 2005 |
Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats.
Topics: Animals; Animals, Genetically Modified; Atrasentan; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Endothelin A Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heart Ventricles; Hypertension; Kidney; Male; Myocardium; Organ Size; Osmolar Concentration; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Renin; Sodium Chloride, Dietary; Sulfonamides; Survival Analysis | 2005 |
Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atrasentan; Bosentan; Carrageenan; Celecoxib; Cold Temperature; Dexamethasone; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelin-1; Endothelins; Grooming; Hyperalgesia; Indomethacin; Male; Maxillary Nerve; Nerve Compression Syndromes; Oligopeptides; Peptide Fragments; Peptides, Cyclic; Piperidines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Trigeminal Neuralgia | 2006 |
Endothelin ET(B) receptor antagonist reduces mechanical allodynia in rats with trigeminal neuropathic pain.
Topics: Animals; Atrasentan; Bosentan; Drug Therapy, Combination; Endothelin B Receptor Antagonists; Endothelin-1; Male; Pain; Pain Threshold; Pyrrolidines; Pyrrolidinones; Rats; Rats, Wistar; Sulfonamides; Time Factors; Trigeminal Neuralgia | 2006 |
Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats.
Topics: Animals; Animals, Genetically Modified; Antihypertensive Agents; Atrasentan; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heterozygote; Hypertension; Male; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Renin; Sodium Chloride, Dietary; Sulfonamides; Time Factors | 2006 |
Effect of endothelin receptor antagonists on ventricular susceptibility in postinfarcted rats.
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atrasentan; Blotting, Western; Bosentan; Cardiac Pacing, Artificial; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; GAP-43 Protein; Hemodynamics; Hydralazine; Immunohistochemistry; Male; Methoxyhydroxyphenylglycol; Myocardial Infarction; Myocardium; Nerve Growth Factor; Neurofilament Proteins; Norepinephrine; Polymerase Chain Reaction; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; RNA, Messenger; Sulfonamides; Sympathetic Nervous System; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation | 2008 |
Up-regulation of endothelin type a receptor in human and rat radiation proctitis: preclinical therapeutic approach with endothelin receptor blockade.
Topics: Animals; Atrasentan; Bosentan; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Humans; Male; Proctitis; Pyrrolidines; Radiation Injuries; Radiation-Protective Agents; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Rectum; RNA, Messenger; Sulfonamides; Up-Regulation | 2009 |
Constriction of rat extra-splenic veins to lipopolysaccharide involves endothelin-1.
Topics: Animals; Atrasentan; Bosentan; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Hypovolemia; Lipopolysaccharides; Male; Mesentery; Myography; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Spleen; Sulfonamides; Vasoconstriction | 2010 |
Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes.
Topics: Animals; Atrasentan; Bosentan; Cerebral Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Male; Pyrrolidines; Rats; Rats, Inbred Strains; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Vasodilator Agents | 2011 |